BOSTON, Jan. 6, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2023 financial results at 6:00 am ET on Tuesday, February 7, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 7, 2023.
The call can be accessed via teleconference at: Q3 2023 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/m6/p/qyrbnnof https://edge.media-server.com/mmc/p/pt8ugsbv
A replay of the conference call and webcast will be available for one year beginning on February 7, 2023 at 11:00 am ET using the conference call webcast link provided in this press release.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contact:
Olga Guyette, Sr. Director, Investor Relations & Treasury
(781) 356-9763
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Josh Gitelson, Director, Global Communications
(781) 356-9776
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$94.40 |
| Daily Change: | 1.07 1.15 |
| Daily Volume: | 359,766 |
| Market Cap: | US$4.790B |
February 21, 2024 February 21, 2024 February 08, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
